Meinhart Antonia, Schmueser Annika, Moritz Steffen, Böge Kerem
University Medical Center Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Martinistrasse 52, 20246 Hamburg, Germany.
Charité - Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany; Medical University Brandenburg, Neuruppin, Fehrbelliner Str. 38, 16816 Neuruppin, German Center of Mental Health (DZPG), Berlin, Germany.
Schizophr Res. 2025 Jul;281:91-107. doi: 10.1016/j.schres.2025.03.040. Epub 2025 May 5.
Mindfulness- and acceptance-based interventions (MBIs/ABIs) for persons with schizophrenia spectrum disorders (SSD) aim to cultivate purposeful attention, mind-body awareness, and targeted action-taking. This systematic meta-review assessed the current body of evidence regarding the effects of MBIs/ABIs for SSD symptoms.
The study was registered with PROSPERO (CRD42024535284) on June 3, 2024. Seven databases were searched between April 18 and April 19, 2024. Meta-analyses investigating the effects of MBIs/ABIs for SSD symptoms were considered. Two authors (AM, AS) independently completed data extraction and analysis. Evidence grading and methodology assessments were conducted using the Ioannidis' criteria, AMSTAR-2, and AMSTAR-Plus Content guidelines.
A total of 18 meta-analyses with up to 2572 participants were considered; 14 studies were eligible for analysis. Results were classified according to Ioannidis' criteria; the effect size of the highest ranked study with the largest number of primary studies is presented. Percentages indicate the number of studies reporting significant results. Significant evidence was found at end of treatment for overall symptomatology (MBIs: 100 %, n = 9, g = -0·7 (total range: -0·417 to -1·152), 95% CI: [-1·052, -0·347], I = 95·36; ABIs: 25 %, n = 29, g = -1·065 (total range: -0·1 to -1·065) [-1·371, -0·759], I = 85·1), positive (MBIs: 50 %, n = 6, g = -0·296 (total range: -0·155 to -0·416) [-0·528, -0·064], I = 34·69; ABIs: 33·33 %, n = 3, g = -0·602 (total range: -0·602 to 0·147) [-1·014, -0·191], I = 0), negative (MBIs: 100 %, n = 8, g = -0·94 (total range: -0·384 to -0.98) [-1·466, -0·413], I = 86·42; ABIs: 25 %, n = 2, g = -0·631 (total range: -0·028 to -0.631) [-1·108, -1·154], I = 0), affective symptoms (MBIs: 50 %, n = 9, g = -0·971 (total range: -0·275 to -0·971) [-1·413, -0·529], I = 91·32; ABIs: 33·33 %, n = 3, g = -0·854 (total range: -0·472 to -0·854) [-1·255, -0·453, I = 0), social functioning (MBIs: 100 %, n = 7, g = -1·368 (total range: -0·452 to -1·368) [-2·194, -0·542], I = 94·3; ABIs: g total range: -0·878 to 0·625), mindfulness (MBIs: 66·66 %, n = 5, g = -0·805 (total range: -0·488 to -1·429) [-1·16, -0·45], I = 0; ABIs: 66·66 %, n = 1, g = -0·959 (total range: -0·391 to -0·959) [-1·788, -0·129], I = NA), and acceptance (MBIs: g total range: -0·381 to 0·381; ABIs: 50 %, n = 4, g = -0·393 (total range: -0·393 to 0·398) [-0·673, -0·113], I = 0). Possible explanations for the differences in effect sizes for MBIs and ABIs are explored. Methodological assessments ranked 'low' or 'critically low' for all meta-analyses.
Although subject to several limitations, significant small to large effect sizes were evident for overall symptomatology, mindfulness, and social functioning. Small to large effect sizes were found for positive, negative, and affective symptoms. Future research should incorporate additional risk of bias assessments, increased sample sizes, and consider cultural contexts (as the largest effect sizes were reported by studies with a majority of samples from Mainland China and Hong Kong) regarding the therapeutic benefits of MBIs/ABIs.
There was no funding source for this study.
针对精神分裂症谱系障碍(SSD)患者的正念和接纳为基础的干预措施(MBIs/ABIs)旨在培养有目的的注意力、身心意识和有针对性的行动。这项系统的荟萃分析评估了当前关于MBIs/ABIs对SSD症状影响的证据。
该研究于2024年6月3日在PROSPERO(CRD42024535284)注册。在2024年4月18日至4月19日期间检索了七个数据库。纳入了调查MBIs/ABIs对SSD症状影响的荟萃分析。两位作者(AM,AS)独立完成数据提取和分析。使用Ioannidis标准、AMSTAR - 2和AMSTAR - Plus内容指南进行证据分级和方法学评估。
共纳入18项荟萃分析,涉及多达2572名参与者;14项研究符合分析条件。结果根据Ioannidis标准分类;呈现了纳入原始研究数量最多且排名最高的研究的效应量。百分比表示报告有显著结果的研究数量。在治疗结束时,发现总体症状(MBIs:100%,n = 9,g = -0·7(总范围:-0·417至-1·152),95% CI:[-1·052,-0·347],I = 95·36;ABIs:25%,n = 29,g = -1·065(总范围:-0·1至-1·065)[-1·371,-0·759],I = 85·1)、阳性症状(MBIs:50%,n = 6,g = -0·296(总范围:-0·155至-0·416)[-0·528,-0·064],I = 34·69;ABIs:33·33%,n = 3,g = -0·602(总范围:-0·602至0·147)[-1·014,-0·191],I = 0)、阴性症状(MBIs:100%,n = 8,g = -0·94(总范围:-0·384至-0.98)[-1·466,-0·413],I = 86·42;ABIs:25%,n = 2,g = -0·631(总范围:-0·028至-0.631)[-1·108,-1·154],I = 0)、情感症状(MBIs:50%,n = 9,g = -0·971(总范围:-0·275至-0·971)[-1·413,-0·529],I = 91·32;ABIs:33·33%,n = 3,g = -0·854(总范围:-0·472至-0·854)[-1·255,-0·453],I = 0)、社会功能(MBIs:100%,n = 7,g = -1·368(总范围:-0·452至-1·368)[-2·194,-0·542],I = 94·3;ABIs:g总范围:-0·878至0·625)、正念(MBIs:66·66%,n = 5,g = -0·805(总范围:-0·488至-1·429)[-1·16,-0·45],I = 0;ABIs:66·66%,n = 1,g = -0·959(总范围:-0·391至-0·959)[-1·788,-0·129],I = NA)和接纳(MBIs:g总范围:-0·381至0·381;ABIs:50%,n = 4,g = -0·393(总范围:-0·393至0·398)[-0·673,-0·113],I = 0)方面有显著证据。探讨了MBIs和ABIs效应量差异的可能解释。所有荟萃分析的方法学评估均为“低”或“极低”。
尽管存在一些局限性,但在总体症状、正念和社会功能方面,从微小到较大的效应量都很明显。在阳性、阴性和情感症状方面也发现了从微小到较大的效应量。未来的研究应纳入更多的偏倚风险评估、增加样本量,并考虑文化背景(因为大多数样本来自中国大陆和香港的研究报告了最大的效应量)对MBIs/ABIs治疗益处的影响。
本研究无资金来源。